SOURCE: Benda Pharmaceutical, Inc.

March 23, 2007 11:36 ET

Benda Pharmaceutical, Inc. Reconstitutes Board and Appoints Two New Directors

Action Is a Critical Step in the Process of Satisfying NASDAQ Listing Criteria

HUBEI PROVINCE, CHINA -- (MARKET WIRE) -- March 23, 2007 -- Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a Chinese-based pharmaceutical company engaged in the development, manufacturing and distribution of medicines, active pharmaceutical ingredients and pharmaceutical intermediaries (bulk chemicals), announced today that Dr. Q.Y. Ma and Mr. Eric Yu have been appointed to serve on the Company's Board of Directors effective March 20, 2007.

Dr. Ma, Director

Dr. Ma has been the managing director of venture capital firm Time Innovation Ventures since 2000. Dr. Ma has more than eight years of experience in venture capital and private equity investment, M&A and project financing in mainland China. Dr. Ma served as an associate professor in the Department of Electrical Engineering at Columbia University and in the Department of Radiology at Harvard Medical School from 1994 to 2005. He has worked closely in the IT and healthcare industries and served as a technology consultant to IBM, General Electric, TRW Inc. and DuPont. Dr. Ma is a director of ComTech, a co-founder of Semiconductor Manufacturing International Corp., and the Chairman of TiMed. He has served as an adviser to the Ministry of Information Industry, Beijing Government and as senior advisor to Zhangjiang Hi-Tech Park in Shanghai. Dr. Ma received his PhD from Columbia University in 1990 and attended the Executive Program of Stanford University's School of Business.

Eric Yu, Director

Eric Yu Tak Shing currently serves as Benda's Chief Financial Officer. Mr. Yu is a certified public accountant (CPA, Hong Kong and CPA, Australia) with thirteen years of experience in public and corporate accounting and finance, most recently as Financial Controller of Beijing Teletron Telecom Engineering Co., Ltd. Mr. Yu began his career in 1993 with BDO Kwan Wong Tan & Fong, which was acquired by Deloitte Touche Tohmatsu in 1996. He has held progressively more responsible positions with companies in China, Hong Kong, Australia and the United States, gaining in-depth knowledge and understanding of the accounting procedures, standards and issues in accordance with PRC GAAP, US GAAP and Hong Kong GAAP. Mr. Yu is fluent in English, Mandarin and Cantonese. He holds a Bachelor of Commerce Degree in Accountancy and Legal Studies from the University of Wollongong in Australia.

The Benda Board now consists of two Benda officers (Yiqing Wan, Chairman and CEO; and Eric Yu, CFO) and two independent directors (John Micek and Q.Y. Ma). The Board is currently seeking a third independent director who will qualify as a "financial expert" and who will chair Benda's Audit Committee.

John Micek, Director

John Micek is Managing Director of Silicon Prairie Partners, LP, a Palo Alto, California-based venture fund. Before founding Silicon Prairie Partners, John was President of JAL, Inc., a family-owned group of insurance-related companies in Omaha, Nebraska, which markets and services financial products nationwide to financial institutions and credit unions. John is a member of the boards of several technology-based companies including UTEK (a university technology transfer company) and Enova Systems (enabling technology for fuel cell and distributed power management). He is a cum laude graduate of Santa Clara University, and the University of San Francisco School of Law, where he was Senior Articles Editor of the Law Review. He is a practicing California attorney specializing in financial services.

Commenting on the reconstitution of the Benda Board of Directors, Mr. Wan, Chairman and CEO, noted that: "The addition of Dr. Ma and Mr. Yu to our Company's Board of Directors now gives Benda a bona fide and credible board. We recognize that it is especially important for Chinese issuers listed in the U.S. to have truly independent boards to ensure that the interests of stockholders are well represented at all times. Our two independent directors are seasoned and successful entrepreneurs who fully understand what it takes to drive and create value in the public marketplace. The Board is working diligently to find a world-class financial expert to fill the final vacancy. One of Benda's capital market goals over the next 12 months is to achieve a NASDAQ Capital Market listing. Having a strong and independent Board of Directors is a critical step in that process."

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (, is engaged in the business of identifying, discovering, developing, and manufacturing conventional medicines, active pharmaceutical ingredients, bulk chemicals (or pharmaceutical intermediates), and Traditional Chinese Medicines ("TCMs") for the treatment of some of the most widespread common ailments and diseases (e.g. common cold, diabetes, and cancer).


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information